Conversely, more recently, two independent phase 2 trials showed response of neoadjuvant programmed cell death protein 1 (PD-1) therapy in recurrent and operable GBM with response-associated distinct immunogenomic features [6,7,8]. Here, PDCD1 is linked to glioblastoma.